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INTRODUCTION
Recent advances in technology make it possible to fuse ana-
tomical images with functional images. The use of combined
18F-FDG PET/CT (PET/CT) fusion images has been shown to
improve diagnostic accuracy (1-3). For head and neck cancers,
the reported sensitivity of PET/CT is 98%, specificity of 92%,
with an accuracy of 94% for the identification of a malignancy
of the head and neck; this is a higher accuracy than with PET or
CT alone (4). Therefore, the use of the PET/CT potentially
affects the care of patients with head and neck cancer (5). Our
previous study and others have also demonstrated that PET/CT
is more accurate than conventional PET and contrast enhanced
CT (CT) for evaluating the cervical nodes of patients with head
and neck squamous cell carcinoma (6, 7). 
For the evaluation of laryngeal lesions, there have been sev-
eral reports on the efficacy of PET/CT. One recent report showed
that the results of the PET/CT had a major impact on patient
management in 59% of cases with cancer of the larynx with a
higher diagnostic values than PET or CT alone (8). The subjects
evaluated had supraglottic cancer (45%) and glottic cancer (55
%). The major impact of the PET/CT results was on treatment
planning in the post-treatment setting (86%) during evaluations
of disease recurrence and response to treatment, consistent with
previous reports (9, 10). 
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Objectives. The primary aim of this study was to determine whether 18F-FDG-PET/CT (PET/CT) scans provide addi-
tional diagnostic information in addition to the direct laryngoscopic examination (L/E) and contrast-enhanced CT
(CT) in patients with glottic cancer during the initial evaluation. 
Methods. Fifty-five consecutive patients with glottic cancer of the larynx that had L/E, CT and PET/CT were enrolled. The
diagnostic value of each modality was compared for their accuracy in predicting the extent of the primary tumors
on sub-site based analysis and the final tumor staging. The reference standards were either the surgical pathology
findings or clinical/radiological follow-up outcome. Changes in patient care based on PET/CT results were com-
pared with the treatment decisions based on L/E with CT. 
Results. For primary tumor sub-site based analysis, the sensitivity was significantly higher for L/E (92.8%) than for PET/
CT (79.4%, P=0.028). The comparisons between L/E vs. CT and CT vs. PET/CT did not reach statistical signifi-
cance. As an initial tumor-staging method the L/E had a diagnostic accuracy of 76.4%, compared to 61.8% for CT
and 41.8% for PET/CT. The L/E and CT were better than the PET/CT (P=0.0009 and 0.049) for the initial TNM
staging. PET/CT scanning changed the clinical decision-making based on the L/E with CT results in 12.7% of cases,
of whom 5.5% had no additional PET/CT related benefit.
Conclusion. The results of this study showed that PET/CT imaging added no clinical information benefit compared to
the L/E and CT for the initial evaluation of patients with glottic cancer. 
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Original ArticleThe use of PET/CT scanning has become popular for staging
patients with head and neck cancer, identifying response to non-
surgical therapy and allowing earlier detection of disease recur-
rence. However, specific recommendations for its use are need-
ed to determine which patients are good candidates for the use
of PET/CT scanning (11). Therefore, the goal of this study was
to determine the diagnostic value of PET/CT for patients with
glottic cancer by comparing it with direct laryngoscopic exami-
nation and CT for initial tumor staging. In addition, we evaluat-
ed the impact of the PET/CT findings on clinical decision-mak-
ing for patient treatment. 
MATERIALS AND METHODS
Subjects 
From January 2003 to December 2005, 114 patients who were
newly diagnosed with squamous cell carcinomas of the glottic
larynx by biopsy were initially evaluated for inclusion in this
study. Among them, 60 patients had direct laryngoscopic exami-
nations (L/E), CT and PET/CT for tumor staging, and the remain-
ing 54 subjects were excluded because one of the three diagnos-
tic modalities were not performed during the initial evaluation.
Five additional patients were excluded because of incomplete
pathology information 55 patients with glottic cancer were enrolled
in this study. The subjects included 53 men and 2 women and
their age ranged from 37 to 88 year (mean age: 58.4 year). Our
Institutional Review Board approved the protocol for this retro-
spective analysis.
Direct laryngoscopic examinations
All patients underwent laryngeal examination with a laryngeal
telescope and a complete physical examination of the head and
neck in the outpatient clinic; they subsequently underwent
biopsy of their glottic lesions for pathological diagnosis under
general anesthesia.
For the primary tumor sub-site based analysis, we divided the
structure around glottis into 6 sub-sites based on the AJCC stag-
ing manual (6th edition, 2002): ipsi-lateral true vocal fold, con-
tra-lateral true vocal fold, supraglottis, subglottis, paraglottic space,
and thyroid cartilage. First, one head and neck surgeon assessed
the patients with glottic cancer with the knowledge of the patient’s
clinical history. For suspected lesions of the glottis, a direct laryn-
goscopic biopsy was performed with evaluation of the extent of
the primary lesions. With the information of the clinical exami-
nation but without the knowledge of the biopsy results, the physi-
cian determined the status of each sub-site and the clinical initial
staging of the glottic cancer. Each sub-site was classified as malig-
nant-positive, malignant-negative or equivocal. The information
from routine chest x-rays were included in the determination of
the TNM staging along with the clinical examination.
The final diagnosis of squamous cell carcinomas of the glottis
was confirmed pathologically in all patients. Next, the patients
had CT and PET/CT scanning within an interval of one month
before the initiation of any treatment.
Contrast enhanced CT 
CT scans (LightSpeed Ultra or Ultra 16, GE, Milwaukee, WI,
USA) of the head and neck were performed using the following
parameters: 160 mAs, 120 KeV, a section thickness of 3.75 mm,
and a table feed of 8.75 mm per rotation. For contrast enhance-
ment, 90 mL of an iodinated contrast agent (Ultravist 300,
Schering, Berlin) was injected intravenously at 3 mL/sec using
an automated injector. The scan delay time was 30 sec.
For the CT scans, a radiologist determined the extent of the
laryngeal lesion and the status of the cervical lymph nodes; except
for the fact that the patient had laryngeal cancer, the radiologist
had no additional information about the clinical findings. First,
the interpretation of the CT scans focused on the primary lesion
of the larynx. Laryngeal lesions with abnormal enhancement
patterns were evaluated to assess the extent according to the above
sub-sites. The regional lymph nodes of the head and neck were
also evaluated according to accepted criteria (12). The radiolo-
gist then determined the initial staging of the laryngeal lesions
from the information of the standalone CT scans. 
Integrated 18F-FDG PET/CT 
All patients fasted for at least 6 hr prior to the PET/CT scans, which
were performed using a GE Discovery LS 18F-FDG-PET/CT scan-
ner (General Electric, Milwaukee, WI, USA). Whole body CT scan-
ning was performed by a continuous spiral technique using an
8-slice helical CT with a gantry a rotation speed of 0.8 sec. The
CT scan data were collected using the following parameters:
40-80 mAs, 140 KeV, a section width of 5 mm, and a table feed of
5 mm per rotation. No intravenous or oral contrast agents were
used. Following the CT scans, and after the intravenous injection
of 370 MBq 18F-FDG, an emission scan was performed from
the thigh to the head for 5 min per frame for a total of 45 min.
The attenuation-corrected 18F-FDG-PET images using the CT
data were reconstructed with an ordered subset expectation
maximization algorithm (28 subsets, 2 iterations). The images
were displayed in a 128×128 matrix (pixel size=4.29×4.29 mm
with a slice thickness of 4.25 mm). The separate CT and PET scan
data were accurately co-registered using commercial software
(eNTEGRA, Elgems, Haifa, Israel). The standardized uptake val-
ues (SUVs) were acquired using the attenuation-corrected images,
the amount of injected 18F-FDG, the body weight of each patient
and the cross- calibration factors between the 18F-FDG-PET and
the dose calibrator.
For PET/CT interpretation, one nuclear medicine physician
reviewed the fused PET/CT images without knowledge of the
clinical findings except for the fact that the patient had laryngeal
cancer. The nuclear medicine physician first reviewed the
images to determine whether there was abnormal uptake of FDG
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values to determine whether the intensity was higher than that
of the surrounding tissues. The interpretation was revised based
on the anatomical information provided by the combined PET/CT
images. Similar to the interpretation of the CT scans, a nuclear
physician determined the status of each primary tumor sub-site
and the initial staging of the laryngeal lesions from the informa-
tion of the standalone PET/CT scans. 
Decision making for treatment
The head and neck cancer, tumor board determined the treat-
ment plan for the laryngeal lesions after review of the results
from the clinical examination and the CT scans. Then the team
reviewed the PET/CT images. The changes in the  treatment
decisions were recorded. The confirmed T classification of the
primary lesions were 33 (60%) T1a lesions, 9 (16.4%) T1b, 6
(10.9%) T2, 5 (9.1%) T3, and 2 (3.6%) T4a lesions. There were
only two patients with neck node metastases (pN2b: 2, 3.6%).
The final treatment plans were determined after the available
treatment options (curative surgery in 35 patients and radical
radiotherapy in 20 patients as an initial treatment) were review-
ed with each patient.
Analysis 
As the reference standard, either the surgical pathology or the
clinical/radiological follow up outcomes were used for compar-
isons. For the primary tumors, surgical pathology results from the
laryngoscopic biopsies or surgical excision were available for all
patients. However, for the neck nodes, only seven patients had
neck dissections, so clinical/radiological follow up outcomes were
used as the reference standard in the remaining 48 patients.
The mean follow-up period for all subjects was 21.5 months
(range, 12-30 months).
We determined the sensitivity, specificity, positive predictive
value, negative predictive value, and diagnostic accuracy of the
L/E, CT and PET/CT for predicting the extent of disease on
based on the sub-site analysis. The diagnostic accuracy for the
initial tumor staging among three diagnostic modalities was also
compared. Statistical differences between the imaging modali-
ties were analyzed by the McNemar test or the chi-squared test
with Bonferroni’s correction and the 95% confidence interval was
determined by Wilson’s method. Two tailed P-values less than
0.05 were considered to indicate statistical significance. The clin-
ical treatment decisions based on L/E with CT, L/E and CT with
PET/CT were recorded for each patient to determine the impact
of the imaging modality on patient care. 
RESULTS
Diagnostic value based on sub-site analysis of glottic cancer
Analysis of 149 sub-sites in 55 patients were recorded; 55 ipsi-
lateral true vocal folds, 55 contra-lateral true vocal folds, 19 adja-
cent supraglottis, 2 adjacent subglottis, 13 paraglottic areas, and
5 thyroid cartilages. If any of the diagnostic modalities could not
predict the status of the sub-sites, we marked the status of the sub-
sites as ‘unknown’. Clinical examination with laryngoscopy (L/E)
had a sensitivity of 92.8%, specificity of 86.5%, positive predic-
tive value (PPV) 92.8%, negative predictive value (NPV) 88.2%,
and a diagnostic accuracy of 90.6%, compared to 82.5%, 82.7%,
92.0%, 89.6%, 83.9 for CT scans and 79.4%, 86.5%, 98.7%,
83.3%, 85.9% for the PET/CT, respectively (Table 1).
The sensitivity was significantly higher in the L/E than in the
PET/CT (P=0.0279, McNemar test with Bonferroni’s correction).
However, the differences between L/E and CT as well as CT
and PET/CT did not reach statistical significance. Other para-
meters such as specificity, PPV, NPV and diagnostic accuracy
were similar among the three diagnostic modalities.
For the neck nodes, we are unable to analyze the statistical
differences between diagnostic modalities, because of the small
number (two pN+) of pathologically proven regional metastases.
Diagnostic accuracy for initial tumor staging in glottic
cancer
For the initial tumor staging, the L/E had a diagnostic accuracy of
76.4%, compared to 61.8% for CT scans and 41.8% for PET/
CT scanning (Fig. 1; Table 2). The L/E and CT were better than
the PET/CT (P=0.0009 and 0.0492) for the initial TNM staging.
The T and N classifications were determined by each diagnos-
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L/E CT PET/CT
P
�
(%, 95%CI*) (%, 95%CI) (%, 95%CI)
Table 1. Diagnostic accuracy of direct laryngoscopic examinations
(L/E), contrast enhanced CT scans (CT) and PET/CT for  primary
tumor based on subsite analysis in patients with glottic cancer (N=
149 sub-sites)
Sensitivity 92.8 (85.8-96.5) 82.5 (73.7-88.8) 79.4 (70.3-86.2) 0.0759
�
0.0279
�
1.000
‖
Specificity 86.5 (74.7-93.3) 82.7 (70.3-90.6) 86.5 (74.7-93.3) 1.000
�
1.000
�
1.000
‖
Positive 92.8 (85.8-96.5) 92.0 (84.3-96.1) 98.7 (93.1-99.8) 1.000
�
predictive 0.150
�
value 0.249
‖
Negative 88.2 (76.6-94.5) 89.6 (77.8-95.5) 83.3 (71.3-91.0) 1.000
�
predictive 1.000
�
value 1.000
‖
Diagnostic 90.6 (84.8-94.3) 83.9 (77.2-88.9) 85.9 (79.4-90.6) 0.150
�
accuracy 0.670
�
1.000
‖
*95% CI: 95% Confidence interval using Wilson’s method. 
� Comparison me-
thod between test modalities: McNemar test with Bonferroni’s correction or
chi-square test with Bonferroni’s correction. 
� L/E vs. CT. 
�L/E vs. PET/CT. 
‖CT
vs. PET/CT.tic modality alone; however, the M classification of the TNM stag-
ing was determined by the information from routine chest x-rays,
L/E and CT. In cases with PET/CT scanning, all T, N and M clas-
sifications were determined solely by the results of the PET/CT.
Changes of clinical decisions for treatment
The clinical decisions for treatment based on the L/E and CT
results were changed by the added PET/CT information in seven
of 55 cases (12.7%). In two patients, one additional diagnostic
direct laryngoscopy procedure, under general anesthesia, was
needed for re-evaluation of the primary site because of a discrep-
ancy in the results from L/E, CT and PET/CT. In addition, the
PET/CT changed an elective neck dissection to a curative neck
dissection in four patients based on the hot uptake of FDG-glu-
cose in the neck nodes. In one patient, the PET/CT changed the
irradiation field and dose to cover the suspected neck nodes.
Among the seven patients, for whom the PET/CT changed
the treatment planning, six patients had curative surgery for their
lesions, and one had curative radiotherapy. The final surgical
pathology revealed that one T classification and two N classifi-
cations, previously determined by PET/CT, were incorrect. Three
patients were over-treated based on the results of the PET/CT
at one primary and two neck sites. However, in four patients the
results of the PET/CT were consistent with the final pathology
findings and clinical follow-up data (regression of enlarged neck
nodes in size and the drop of uptake value after completion of
irradiation in one who had received radical radiotherapy). 
DISCUSSION
The goal of this study was to determine whether PET/CT scans
provided additional information that was of diagnostic benefit
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Fig. 1. A 62-year-old man with glottic squamous cell carcinomas in the left vocal fold. (A) Preoperative laryngoscopy shows irregular surfaced
mucosal change confined to the left true vocal fold, suggesting malignant lesions, T1a. (B) The CT scans were interpreted as T1a glottic cancer,
based on mucosal irregularity and abnormal contrast enhancement of the left true vocal fold. (C, D) On the PET/CT images, the left epiglottis
and vallecula area showed asymmetrical increased uptake of FDG (peak standard uptake value=6.3) suggesting a malignancy, but the faint
uptake in the left true vocal fold (peak standard uptake value=2.3) was considered benign. (E) The CT images of the corresponding site also
revealed small enhancing lesions of the vallecula, but the radiologist interpreted the lesion as benign changes of the lingual tonsil. The initial
tumor staging predicted by PET/CT standalone was supraglottic cancer cT2N0M0. The final surgical pathology demonstrated malignant cells
only in the left true vocal fold without extension to supraglottis (T1a).
A B
D E C
L/E CT PET/CT
P
�
(%, 95% CI*) (%, 95% CI) (%, 95% CI)
Table 2. Prediction of initial tumor staging by using direct laryngo-
scopic examination (L/E), contrast enhanced CT scans (CT), and
PET/CT in patients with glottic cancer (N=55)
*95% CI: 95% Confidence interval using Wilson’s method. 
� Comparison me-
thod between test modalities: McNemar test with Bonferroni’s correction or
chi-square test with Bonferroni’s correction. 
� L/E vs. CT. 
�L/E vs. PET/CT. 
‖CT
vs. PET/CT.
Diagnostic 76.4 (63.7-85.6) 61.8 (48.6-73.5) 41.8 (29.7-55.0) 0.264
�
accuracy 0.0009
�
0.0492
‖compared to the L/E and CT in patients with primary glottic
cancer during the initial evaluation of tumors. The results from
this study demonstrated that adding PET/CT scans to the con-
ventional diagnostic modalities such as L/E and CT scans did
not provide additional benefit. In addition, the impact of the
PET/CT findings on clinical decision making for treatment was
minimal compared to the management decisions without the
PET/CT information. Some of the changes based on the PET/CT,
resulted in over treating patients. 
PET/CT has been reported to have promising diagnostic bene-
fits in patients with head and neck cancer (4-7). However, malig-
nancies at certain sites of the head and neck, for example, pap-
illary thyroid carcinomas, have not been shown to benefit from
PET/CT scanning (13). Glottic cancers have unique clinical fea-
tures and natural history. Early cancers of the larynx produce
hoarseness, allowing earlier recognition and a more favorable
prognosis, especially for tumors developing in the glottis (14, 15).
Only one article was available in PubMed on the diagnostic
value of PET/CT scanning for laryngeal cancer patients (8).
However, studies on the PET/CT for the initial diagnostic work-
up of patients with glottic cancer are not available. This is the
first study to determine the role of PET/CT in the initial evalua-
tion of patients with glottic cancer. In our clinical experience,
PET/CT is beneficial for the diagnosis of disease recurrence after
initial treatment and for the evaluation of advanced laryngeal
cancer (unpublished data). For example, it can be used to differ-
entiate the laryngeal edema of normal mucosa from recurrent
tumor after radiotherapy. In addition, direct laryngoscopic biop-
sy is reported to have a low specificity and negative predictive
value for the diagnosis of recurrence post-radiotherapy. In some
cases, the conventional CT images may provide more informa-
tion than the laryngoscopic evaluation. However, for patients
with primary glottic cancer the situation is different. Our results
showed that the PET/CT findings added to the conventional work-
up for the initial evaluation of glottic cancer did not demonstrate
a diagnostic advantage that would support the additional cost of
the PET/CT. 
The glottis can be easily evaluated by physical examination
with the aide of laryngoscopy. This is another reason why the
clinical examination with laryngoscopy showed good diagnostic
accuracy comparable to that of the CT; it resulted in only three
equivocal lesions compared to the results of the CT and PET/CT
(16 lesions and 18 lesions respectively). In this study, we per-
formed the biopsy of primary tumor site with direct laryngo-
scopic evaluation under general anesthesia, and then the CT and
PET/CT were performed. Because glottic cancers can be accessed
without difficulty, other imaging modalities are not necessary to
guide the biopsy, unlike recurrent or post-radiotherapy cases. 
In the present study, there were five cases where only the
PET/CT erroneously diagnosed the N stage as negative for malig-
nancy, but the lesion proved to be positive by the final patholo-
gy. In addition, it misdiagnosed one case with distant metastases
that was shown to be inflammatory lesions on the follow up
chest CT. For the evaluation of distant metastases in patients
with glottic cancer, a simple chest x-ray, blood testing including
a liver function profile or abdominal ultrasonography are all
cost-effective tests. However, there is no data to suggest that
the PET/CT adds additional significant information for patient
management.
The results of this study also showed that the information from
the L/E and CT was sufficient to make a correct diagnosis and
implement an appropriate treatment plan in most patients. The
results of the PET/CT affected patient care in only seven cases
and correct results were confirmed in only three of the seven
patients. 
This study has several limitations. The study population con-
sisted of 48 patients with early glottic cancer (T1 or T2N0M0)
(87.3%); therefore the results do not apply to other stages of
glottic cancer. The clinical course of patients with advanced glot-
tic cancer differs from early glottic cancer, and these cases may
benefit from PET/CT scanning; however, further study is need-
ed for confirmation of such a benefit. 
Another limitation of this study was that the CT and PET/CT
were performed after biopsy of the primary tumor sites. In most
of patients, the CT was performed within two weeks after the
biopsy and the PET/CT at a mean of three weeks after the biop-
sy. The prior biopsy procedure may have confounded the eval-
uation of the extent of the primary lesions by CT and PET/CT,
and may have resulted in the over-estimation of the T classifi-
cation, although the biopsy of the primary sites removed only
small representative samples from the tumors. In summary, the
results of this study showed that for the initial evaluation of
patients with glottic cancer, the combined PET/CT imaging did
not provide additional information, useful for patient manage-
ment, compared to the standard L/E and CT. 
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